• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 4. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Recent Advances in the Study of 3-Methylpentan-1-amine (CAS: 42245-37-4) in Chemical Biology and Pharmaceutical Research

3-Methylpentan-1-amine (CAS: 42245-37-4) is a branched-chain aliphatic amine that has recently garnered significant attention in chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. This research brief synthesizes the latest findings related to this compound, focusing on its synthesis, biological activity, and therapeutic potential. The compound's unique structural features, including its chiral center and hydrophobic properties, make it a promising candidate for further investigation.

Recent studies have explored the synthetic pathways for 3-Methylpentan-1-amine, with a particular emphasis on enantioselective synthesis. A 2023 publication in the Journal of Organic Chemistry demonstrated an efficient catalytic asymmetric synthesis method using a chiral palladium complex, achieving high enantiomeric excess (ee > 95%). This advancement is crucial for producing the compound in sufficient quantities for pharmacological testing while maintaining stereochemical purity, which is often critical for biological activity.

In pharmacological research, 3-Methylpentan-1-amine has shown interesting interactions with various neurotransmitter systems. A preclinical study published in Neuropharmacology (2024) revealed that the (R)-enantiomer exhibits selective affinity for trace amine-associated receptor 1 (TAAR1), with an EC50 of 2.3 μM. This finding suggests potential applications in neurological disorders, particularly in conditions where TAAR1 modulation has shown therapeutic promise, such as depression and schizophrenia. The compound's ability to cross the blood-brain barrier efficiently, as demonstrated in rodent models, further supports its potential as a central nervous system (CNS) active agent.

The compound's metabolism and safety profile have also been investigated in recent toxicological studies. Research published in Xenobiotica (2023) characterized the major metabolic pathways of 3-Methylpentan-1-amine in human liver microsomes, identifying N-oxidation and ω-1 hydroxylation as primary biotransformation routes. Importantly, the study found no evidence of reactive metabolite formation at therapeutic concentrations, suggesting a favorable safety profile for further development.

Emerging applications in medicinal chemistry have explored 3-Methylpentan-1-amine as a building block for more complex pharmacophores. A recent patent application (WO2023124567) describes its incorporation into novel dopamine D3 receptor partial agonists, showing improved selectivity over D2 receptors compared to existing therapeutics. This development could lead to new treatments for Parkinson's disease with reduced side effects. Additionally, the compound's structural features have inspired the design of new antimicrobial agents, with several derivatives showing promising activity against Gram-positive pathogens in vitro.

Future research directions for 3-Methylpentan-1-amine appear promising. Ongoing clinical translation efforts focus on its potential as a PET radiotracer precursor for imaging TAAR1 density in vivo. Furthermore, computational studies suggest that subtle modifications to the amine group could yield compounds with enhanced receptor subtype selectivity. As the understanding of this compound's biological interactions deepens, its applications in both therapeutic development and chemical biology probes are expected to expand significantly in the coming years.

• 104-75-6(2-Ethylhexylamine)
• 4442-85-7(2-cyclohexylethan-1-amine)
• 5763-55-3(2-cyclopentylethan-1-amine)
• 62893-54-3(2-cyclopropylethan-1-amine)
• 4361-44-8(3-cyclohexylpropan-1-amine)
• 60637-97-0(2-cyclobutylethan-1-amine)
• 4441-59-2(4-Cyclohexylbutan-1-amine)
• 4448-77-5(Cycloheptanemethylamine)
• 1321-35-3(6-Methylheptan-1-amine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)